The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers

Journal of Clinical Pharmacology

Volumn 42, Issue 10, 2002, Pages 1159-1164

  Tsutsumi, Kimiko ^a   Kotegawa, Tsutomu ^a   Kuranari, Masae ^a   Otani, Yasukiyo ^a   Morimoto, Takuya ^a   Matsuki, Shunji ^a   Nakano, Shigeyuki ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYCLOSPORIN; DIGOSIN; DIGOXIN; ERYTHROMYCIN; FELODIPINE; ITRACONAZOLE; MACROLIDE; QUINIDINE; RIFAMPICIN; SIMVASTATIN; TALINOLOL; TRIAZOLAM; VERAPAMIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIGOXIN BLOOD LEVEL; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; HUMAN; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; CARDIOTONIC AGENTS; CLARITHROMYCIN; DIGOXIN; DRUG INTERACTIONS; ERYTHROMYCIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE;

EID: 0036786390     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002401382641     Document Type: Article

References (45)

1. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure. New Engl J Med 1997;336:525-533.
2. Mayer U, Wagenaar E, Beijnen JH, Smit JW, Meijer DKG, van Asperen J, et al: Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr1a P-glycoprotein. Br J Pharmacol 1996;119:1038-1044.
3. Shinkel AH, Mayer U, Wageraar E, Mol CAAM, van Deemter L, Smit JJM, et al: Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 1997;94:4028-4033.
4. Cavet ME, West M, Simmons NL: Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 1996;118:1389-1396.
5. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, et al: Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 1992;263:840-845.
6. Ito S, Woodland C, Harper PA, Koren G: P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model. Life Sci 1993;53:PL25-31.
7. Hori R, Okamura N, Aiba T, Tanigawara Y: Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 196;266:1620-1625.
8. Su S-F, Hung J-D: Inhibition of the intestinal digoxin absorption and exsorption by quinidine. Drug Metab Dispos 1996;24:142-146.
9. Mordel A, Halkin H, Zulty L, Almog S, Ezra D: Quinidine enhances digitalis toxicity at therapeutic serum digoxin levels. Clin Pharmacol Ther 1993;52:457-462.
10. Angelin B, Arvidsson A, Dahlqvist R, Headman A, Schenck-Gustafsson K: Quinidine reduces biliary clearance of digoxin in man. Eur J Clin Invest 1987;17:262-265.
11. Pedersen KE, Christiansen BD, Klitgaard NA, Nielsen-Kudsk F: Effect of quinidine on digoxin bioavailability. Eur J Clin Pharmacol 1983;24:41-47.
12. Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J: Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther 1988;43:668-672.
13. Klein HO, Lang R, Weiss E, Segni ED, Libhaber C, Guerrero J, et al: The influence of verapamil on serum digoxin concentration. Circulation 1982;65:998-1003.
14. Okamura N, Hirai M, Tanigawara Y, Tanaka K, Yasuhara M, Ueda K, et al: Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 1993;266:1614-1619.
15. Robieux I, Dorian P, Klein J, Chung D, Zborowska-Sluiz D, Ogilvie R, et al: The effects of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics. J Clin Pharmacol 1992;32:338-343.
16. Jalava K-M, Partanen J, Neuvonen PJ: Itraconazol decreases renal clearance of digoxin. Ther Drug Monit 1997;19:609-613.
17. Nishihara K, Hibino J, Kotaki H, Sawada Y, Iga T: Effect of itraconazol on pharmacokinetics of digoxin in guinea pigs. Biopharm Drug Dispos 1999;20:145-149.
18. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, et al: Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 2000;68:6-12.
19. Wakasugi H, Yano I, Ito H, Hashida T, Futami T, Nohara R, et al: Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64:123-128.
20. Laberge P, Martineau P: Clarithromycin-induced digoxin intoxication. Ann Pharmacother 1997;31:999-1002.
21. Nawarskas J, McCarthy DM, Spinler SA: Digoxin toxicity secondary to clarithromycin therapy. Ann Pharmacother 1997;31:864-866.
22. Maxwell DL, Gilmour-White SK, Hall MR: Digoxin toxicity due to interaction of digoxin with erythromycin. Br Med J 1989;298:572.
23. Nørregaard-Hnawn K, Klitgaard NA, Pedersen KE: The significance of the enterohepatic circulation on the metabolism of digoxin in patients with the ability of intestinal conversion of the drug. Acta Med Scand 1986;220:89-92.
24. Morton MR, Cooper JW: Erythromycin-induced digoxin toxicity. Ann Pharmacother 1989;23:668-670.
25. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR: Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 1981;305:789-794.
26. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T: A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-dyn 1981;4:879-885.
27. Gault H, Kalra J, Ahmed M, Kepkay D, Longerich L, Barrowman J: Influence of gastric pH on digoxin biotransformation: II. Extractable urinary metabolites. Clin Pharmacol Ther 1981;29:181-190.
28. Takano M, Hsegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T: Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998;358:289-294.
29. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M: Transport of rhodamine 123, a P-glycoprotein substrate, across intestine and Caco-2 cell monolayers in the presence of cytochrome P450 3A-related compounds. J Pharmacol Exp Ther 1999;289:149-155.
30. Mayer U, Wagenaar E, Dorobek B, Beijnen JH, Borst P, Shinkel AH: Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest 1997;100:2430-2436.
31. Noé B, Hagenbuch B, Stieger B, Meier PJ: Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proc Natl Acad Sci USA 1997;94:10346-10350.
32. Halkin H, Sheiner LB, Peck CC, Melmon KL: Determination of the renal clearance of digoxin. Clin Pharmacol Ther 1975;17:385-394.
33. Steiness E, Waldorf S, Hansen PB: Renal digoxin clearance: dependence on plasma digoxin and diuresis. Eur J Clin Pharmacol 1982;23:151-154.
34. Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, et al: Atrovostatin coadministration may increase digoxin concentration by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol 2000;40:91-98.
35. Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, et al: Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 1991;49:256-262.
36. Greiner B, Eichelbaum M, Fritz P, Kreichgauer H-P, von Richter O, Zundler J, Kroemer H: The role of intestinal P-glycoprotein in the interaction of digoxin and rifampim. J Clin Invest 1999;104:147-153.
37. Hinderling PH, Hartman D: Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit 1991;13:381-401.
38. Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J: Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm 1975;3:181-192.
39. Wang L, Kitaichi K, Hui CS, Takagi K, Takagi K, Sakai M, et al: Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol 2000;27:587-593.
40. Wilson JT, van Boxtel CJ: Pharmacokinetics of erythromycin in man. Antibiotics Chemother 1978;25:181-203.
41. Peters DH, Clissold SP: Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992;44:117-164.
42. Ludden TM: Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985;10:63-79.
43. Bailey DG, Bend JR, Arnold MO, Tran LT, Spence JD: Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther 1996;60:25-33.
44. Greenblat DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol ALB, et al: Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 1998;64:278-285.
45. Kantola T, Kivistö KT, Neuvonen PJ: Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-182.